Novoeight
Drug
Novo Nordisk AS
Total Payments
$1.1M
Transactions
1,076
Doctors
462
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5,105 | 61 | 40 |
| 2023 | $1,921 | 99 | 93 |
| 2022 | $12,071 | 66 | 56 |
| 2021 | $11,405 | 88 | 62 |
| 2020 | $20,836 | 82 | 55 |
| 2019 | $250,564 | 335 | 193 |
| 2018 | $385,479 | 116 | 24 |
| 2017 | $444,474 | 229 | 71 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $759,616 | 182 | 67.1% |
| Travel and Lodging | $187,925 | 93 | 16.6% |
| Consulting Fee | $97,368 | 29 | 8.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $55,765 | 13 | 4.9% |
| Food and Beverage | $21,954 | 751 | 1.9% |
| Space rental or facility fees (teaching hospital only) | $9,100 | 4 | 0.8% |
| Education | $129.08 | 4 | 0.0% |
Payments by Type
Research
$759,616
182 transactions
General
$372,240
894 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NN7008-3809 | Novo Nordisk AS | $350,498 | 0 |
| Hemophilia-Related Distress: New Scale Development and Validation | Novo Nordisk Inc | $184,748 | 0 |
| NN7008-4239 | Novo Nordisk AS | $142,380 | 0 |
| NN7008-3553 | Novo Nordisk AS | $79,668 | 0 |
| NN7008-3568 | Novo Nordisk AS | $2,321 | 0 |
Top Doctors Receiving Payments for Novoeight
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Paula Groncy | — | Long Beach, CA | $777,726 | 193 |
| , MD | Hematology | Iowa City, IA | $48,185 | 16 |
| Hassan Yaish | Pediatrics | Salt Lake City, UT | $41,286 | 15 |
| , MD | Pediatric Hematology-Oncology | Danbury, CT | $23,378 | 23 |
| , M.D | Hematology | Los Angeles, CA | $21,455 | 24 |
| , MD, MPH | Pediatrics | San Juan, PR | $21,210 | 9 |
| , MD | Pediatrics | Detroit, MI | $20,660 | 5 |
| , M.D | Internal Medicine | Houston, TX | $19,969 | 3 |
| , M.D | Pediatric Hematology-Oncology | Los Angeles, CA | $17,673 | 11 |
| , MD | Pediatric Hematology-Oncology | Peoria, IL | $16,124 | 12 |
| , M.D | Contractor | Englewood, CO | $15,214 | 5 |
| , MD | Pediatric Hematology-Oncology | New Orleans, LA | $12,811 | 8 |
| Richard Lemons | Pediatric Hematology-Oncology | Salt Lake City, UT | $12,376 | 4 |
| , M.D | Pediatric Hematology-Oncology | Cincinnati, OH | $12,186 | 4 |
| , MD | Pediatric Hematology-Oncology | Macon, GA | $11,729 | 3 |
| , M.D | Pediatrics | Charlottesville, VA | $11,095 | 5 |
| , M.D | Pediatric Hematology-Oncology | Tampa, FL | $9,334 | 4 |
| , MD | Internal Medicine | Minneapolis, MN | $6,490 | 4 |
| , MD | Pediatric Hematology-Oncology | Ann Arbor, MI | $4,430 | 3 |
| , M.D | Pediatric Hematology-Oncology | Lansing, MI | $4,005 | 2 |
| , MD | Internal Medicine | La Jolla, CA | $3,750 | 1 |
| , MD | Pediatric Hematology-Oncology | Beaufort, SC | $1,347 | 3 |
| , MD | Pediatrics | Fontana, CA | $977.35 | 11 |
| , M.D | Pediatrics | Las Vegas, NV | $693.75 | 13 |
| , MD | Pediatric Hematology-Oncology | Las Vegas, NV | $667.55 | 8 |
Ad
Manufacturing Companies
- Novo Nordisk AS $705,504
- Novo Nordisk Inc $309,729
- Novo Nordisk Health Care AG $116,623
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 462
- Transactions 1,076
About Novoeight
Novoeight is a drug associated with $1.1M in payments to 462 healthcare providers, recorded across 1,076 transactions in the CMS Open Payments database. The primary manufacturer is Novo Nordisk AS.
Payment data is available from 2017 to 2024. In 2024, $5,105 was paid across 61 transactions to 40 doctors.
The most common payment nature for Novoeight is "Unspecified" ($759,616, 67.1% of total).
Novoeight is associated with 5 research studies, including "NN7008-3809" ($350,498).